JP2025032196A5 - - Google Patents
Info
- Publication number
- JP2025032196A5 JP2025032196A5 JP2024211090A JP2024211090A JP2025032196A5 JP 2025032196 A5 JP2025032196 A5 JP 2025032196A5 JP 2024211090 A JP2024211090 A JP 2024211090A JP 2024211090 A JP2024211090 A JP 2024211090A JP 2025032196 A5 JP2025032196 A5 JP 2025032196A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- membered
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163167331P | 2021-03-29 | 2021-03-29 | |
| US63/167,331 | 2021-03-29 | ||
| JP2023560087A JP7705475B2 (ja) | 2021-03-29 | 2022-03-25 | Ｋｈｋ阻害剤 |
| PCT/US2022/021912 WO2022212194A1 (en) | 2021-03-29 | 2022-03-25 | Khk inhibitors |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560087A Division JP7705475B2 (ja) | 2021-03-29 | 2022-03-25 | Ｋｈｋ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025032196A JP2025032196A (ja) | 2025-03-11 |
| JP2025032196A5 true JP2025032196A5 (enExample) | 2025-09-04 |
| JP7778900B2 JP7778900B2 (ja) | 2025-12-02 |
Family
ID=81388962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560087A Active JP7705475B2 (ja) | 2021-03-29 | 2022-03-25 | Ｋｈｋ阻害剤 |
| JP2024211090A Active JP7778900B2 (ja) | 2021-03-29 | 2024-12-04 | Ｋｈｋ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560087A Active JP7705475B2 (ja) | 2021-03-29 | 2022-03-25 | Ｋｈｋ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12410160B2 (enExample) |
| EP (1) | EP4313967B1 (enExample) |
| JP (2) | JP7705475B2 (enExample) |
| KR (1) | KR20230158542A (enExample) |
| CN (1) | CN117120429A (enExample) |
| AR (1) | AR125238A1 (enExample) |
| AU (2) | AU2022252182B2 (enExample) |
| CA (1) | CA3214961A1 (enExample) |
| TW (2) | TWI855308B (enExample) |
| WO (1) | WO2022212194A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023121378A1 (ko) * | 2021-12-24 | 2023-06-29 | 주식회사 엘지화학 | (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
| JP2025534728A (ja) * | 2022-10-24 | 2025-10-17 | ユーハン・コーポレイション | ジメチル－２，３－ジヒドロ－１ｈ－インデン誘導体の改良された製造方法 |
| WO2024125482A1 (zh) * | 2022-12-13 | 2024-06-20 | 华领医药技术（上海）有限公司 | 作为己酮糖激酶抑制剂的化合物、其用途以及包含其的组合物 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041443A (en) * | 1989-02-21 | 1991-08-20 | Dainippon Pharmaceutical Co., Ltd. | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof |
| US5137890A (en) | 1990-02-14 | 1992-08-11 | Ortho Pharmaceutical Corporation | 4-phenyl tetrahydropyrido(4,3-d)pyrimidines |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| WO2004081009A1 (en) * | 2003-03-12 | 2004-09-23 | Millennium Pharmaceuticals, Inc. | Quinazoline derivatives as tgf-beta inhibitors |
| JP2007510642A (ja) * | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| EP1928461B1 (en) | 2005-08-04 | 2012-01-04 | Janssen Pharmaceutica NV | Pyrimidine compounds as serotonin receptor modulators |
| US7851468B2 (en) * | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| WO2009045174A1 (en) | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| US8829011B2 (en) | 2008-10-29 | 2014-09-09 | Janssen Pharmaceutica Nv | 2-aminopyrimidine compounds as serotonin receptor modulators |
| KR20110098908A (ko) * | 2008-11-11 | 2011-09-02 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | ＰＩ3Ｋ/ｍＴＯＲ 키나제 억제제 |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| JP2013525370A (ja) | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| LT3329919T (lt) | 2011-11-11 | 2020-02-10 | Gilead Apollo, Llc | Acc inhibitoriai ir jų panaudojimas |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| CN103467482B (zh) * | 2012-04-10 | 2017-05-10 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用 |
| NZ729678A (en) | 2014-09-24 | 2018-07-27 | Gilead Sciences Inc | Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist |
| BR112017013382A2 (pt) | 2014-12-23 | 2018-02-14 | Gilead Sciences Inc | método para preparar um composto, composto, e, ácido. |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| CN107106873A (zh) | 2015-01-09 | 2017-08-29 | 吉利德阿波罗公司 | 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗 |
| WO2017027611A2 (en) * | 2015-08-10 | 2017-02-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers of methylglyoxal and related methods thereof |
| AU2016380920B2 (en) | 2015-12-29 | 2019-10-31 | Pfizer Inc. | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| TWI844474B (zh) | 2016-03-02 | 2024-06-01 | 美商基利阿波羅有限責任公司 | 噻吩并嘧啶二酮acc抑制劑之固體型式及其製造方法 |
| US10519165B2 (en) | 2017-03-03 | 2019-12-31 | Gilead Sciences, Inc. | Processes for preparing ACC inhibitors and solid forms thereof |
| WO2018170517A1 (en) | 2017-03-17 | 2018-09-20 | Regents Of The University Of Colorado, A Body Corporate | Indazole inhibitors of fructokinase (khk) and methods of use in treating khk-mediated disorders or diseases |
| EP4424364A3 (en) | 2017-03-28 | 2024-11-27 | Gilead Sciences, Inc. | Methods of treating liver disease |
| TW201900167A (zh) | 2017-03-28 | 2019-01-01 | 美商基利科學股份有限公司 | 治療肝疾病之方法 |
| AU2018250614A1 (en) | 2017-04-12 | 2019-10-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| US10980810B2 (en) | 2017-10-06 | 2021-04-20 | Gilead Sciences, Inc. | Combination therapy comprising an ACC inhibitor |
| US12161621B2 (en) | 2018-07-16 | 2024-12-10 | The Regents Of The University Of Colorado | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease |
| TWI714231B (zh) | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| KR102558308B1 (ko) | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
| JP7248255B2 (ja) * | 2019-01-29 | 2023-03-29 | シャンドン スアンズ ファーマ カンパニー，リミテッド | ヘキソングルコキナーゼ阻害剤およびその使用 |
| CN118388474A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| WO2020185685A1 (en) | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| WO2020215022A1 (en) | 2019-04-17 | 2020-10-22 | Colorado Research Partners, Llc | Novel compounds and methods of use treating fructose-related disorders or diseases |
| CN111978296A (zh) | 2019-05-22 | 2020-11-24 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| TWI750685B (zh) | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| JP7403661B2 (ja) | 2019-12-24 | 2023-12-22 | 杭州中美華東製薬有限公司 | Ｋｈｋ阻害効果を有する化合物 |
| CN114846008B (zh) | 2019-12-25 | 2024-05-28 | 杭州中美华东制药有限公司 | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 |
| ES2975596T3 (es) | 2020-02-13 | 2024-07-09 | Lilly Co Eli | Compuestos de 2-[2-metilazetidin-1-il]-4-fenil-6-(trifluorometil)-pirimidina |
| CN111423420A (zh) | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| CN114181198B (zh) | 2020-09-15 | 2025-07-15 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类己酮糖激酶抑制剂及其用途 |
| CN116635377A (zh) * | 2020-12-25 | 2023-08-22 | 四川海思科制药有限公司 | 己酮糖激酶抑制剂及其用途 |
| CN114805312A (zh) | 2021-01-29 | 2022-07-29 | 上海拓界生物医药科技有限公司 | 一种己酮糖激酶抑制剂及其制备方法 |
| CN114989143A (zh) | 2021-03-02 | 2022-09-02 | 山东轩竹医药科技有限公司 | 并环类己酮糖激酶抑制剂及其用途 |
| WO2022211595A1 (ko) | 2021-04-01 | 2022-10-06 | 주식회사 엘지화학 | 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물 |
-
2022
- 2022-03-25 KR KR1020237035032A patent/KR20230158542A/ko active Pending
- 2022-03-25 CN CN202280024429.7A patent/CN117120429A/zh active Pending
- 2022-03-25 JP JP2023560087A patent/JP7705475B2/ja active Active
- 2022-03-25 WO PCT/US2022/021912 patent/WO2022212194A1/en not_active Ceased
- 2022-03-25 CA CA3214961A patent/CA3214961A1/en active Pending
- 2022-03-25 AU AU2022252182A patent/AU2022252182B2/en active Active
- 2022-03-25 US US17/704,440 patent/US12410160B2/en active Active
- 2022-03-25 EP EP22719399.2A patent/EP4313967B1/en active Active
- 2022-03-28 TW TW111111557A patent/TWI855308B/zh active
- 2022-03-28 TW TW113132589A patent/TW202448875A/zh unknown
- 2022-03-29 AR ARP220100751A patent/AR125238A1/es not_active Application Discontinuation
-
2024
- 2024-12-04 JP JP2024211090A patent/JP7778900B2/ja active Active
-
2025
- 2025-05-19 AU AU2025203602A patent/AU2025203602A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025032196A5 (enExample) | ||
| WO2022031994A1 (en) | Glp-1r agonists and uses thereof | |
| KR100633844B1 (ko) | 2-시아노-4-플루오로피롤리딘 유도체 또는 그의 염 | |
| Duncia et al. | The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist | |
| KR101351209B1 (ko) | Ｃｂ1 길항제로서 치환된 피페라진 | |
| JP2016512535A5 (enExample) | ||
| US8778881B2 (en) | Peptidic vasopressin receptor agonists | |
| RU2006132463A (ru) | Антагонисты рецептора хемокина | |
| KR20240150488A (ko) | Glp-1r 작용제로서의 화합물 | |
| JPH04308587A (ja) | イミダゾ−ル誘導体およびその製法 | |
| EP1452526A1 (en) | Indole compound and medicinal use thereof | |
| TW201024268A (en) | Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use | |
| JP2005532330A5 (enExample) | ||
| PL181968B1 (pl) | Nowe pochodne peptydowe, sposób wytwarzania pochodnych peptydowych oraz kompozycje farmaceutyczne zawierajace pochodne peptydowe PL | |
| CN101965339A (zh) | 新的儿茶酚衍生物、含有其的药物组合物、儿茶酚衍生物的应用以及药物组合物的应用 | |
| JP2013523642A (ja) | グルカゴン受容体拮抗薬としての新規なスピロイミダゾロン誘導体、組成物およびそれらの使用方法 | |
| WO2021069711A1 (en) | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea | |
| CZ20022305A3 (cs) | Kondenzované azepiny jako vazopresinoví agonisté | |
| EP3939989A1 (en) | Cyclic peptides multimers targeting alpha 4beta 7 integrin | |
| JP2024041835A (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| US6511973B2 (en) | Lactam inhibitors of FXa and method | |
| JPWO2021146370A5 (enExample) | ||
| JP6644825B2 (ja) | 含窒素ベンゾ複素五員環基ピペリジン又はピペラジン誘導体及び薬剤組成物 | |
| JPWO2022034568A5 (enExample) | ||
| CZ20012984A3 (cs) | Phenylalaninolové deriváty |